Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus BUDESONIDE INHALED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus BUDESONIDE INHALED.
AZMACORT vs Budesonide (Inhaled)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Budesonide is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and chemokines, and suppression of airway inflammation.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
200-800 mcg twice daily via inhalation. Maximum 1600 mcg/day.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life is 2-3 hours in adults, reflecting rapid clearance. Clinical context: duration of anti-inflammatory effect may exceed half-life due to receptor binding.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in urine (~60%) and feces (~40%). Less than 10% of unchanged drug is recovered in urine.
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid